Stocks · News reference

8-K filing — IONIS PHARMACEUTICALS INC (IONS)

Sep 4, 2026, 9:00 PMSEC EDGAR

Filed: 2026-09-04 AccNo: 0001140361-26-035802 Size: 181 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IONS

Source: edgar
Observed: Sep 4, 2026, 9:00 PM
Checked: Sep 4, 2026, 9:00 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 4, 2026, 8:41 PMBenzinga Newsdesk
Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. Novartis obtained global rights to develop, manufacture and commercialize pelacarsen under a license and collaboration agreement with the company.
IONS
BenzingaSep 4, 2026, 8:32 PMBenzinga News-desk
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of
IONS NVS
BenzingaSep 4, 2026, 3:59 PMBenzinga Newsdesk
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target
IONS

8-K filing — IONIS PHARMACEUTICALS INC (IONS)

Connected Markets

Related Headlines

Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events

Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target